
Release date: 2024-08-13 16:05:48 Article From: Lucius Laos Recommended: 237
As a potent and selective oral inhibitor targeting FGFR subtypes 1/2/3, Pemigatinib provides a new treatment option for cholangiocarcinoma patients.
The recommended dosage of Pemigatinib is 13.5 mg orally once daily for 14 days, followed by 7 days off for 21 days, and treatment is continued until disease progression or intolerable toxicity. Patients can take this product orally on an empty stomach or with a meal, but they must swallow the tablet whole and not crush, chew, cut, or dissolve the tablet after taking it.
If you miss a dose for more than 4 hours or more, or if you vomit after taking the medication, you do not need to take the prescribed dose on the same day, and you can take the prescribed dose of the medication at the next dose.
Patients with cholangiocarcinoma should also pay attention to appropriate exercise and relaxation training in daily life to enhance their physical fitness, so as to better treat cholangiocarcinoma and enhance the treatment effect.
Patients are encouraged to engage in appropriate recreational activities, such as walking, recreation, etc., to relax the muscles and eliminate tension. These activities not only help to relieve the psychological stress of the patient but also improve the physical fitness of the patient.
Teach patients simple relaxation techniques, such as deep breathing, meditation, etc., to help them self-regulate when they are nervous or anxious.
During the treatment of cholangiocarcinoma patients, the patient's family should provide some support, help the patient build confidence in overcoming the disease, and provide necessary psychological support.
Encourage family members to actively participate in the care process and provide emotional support and care to the patient. Family support and love are essential for the patient's psychological recovery.
Guide patients to use social resources, such as joining patient support organizations, attending rehabilitation talks, etc., to obtain more information and support.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3012025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643